NICE Finally Recommends Alzheimer's Therapies For Mild Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
New clinical data lead U.K.'s cost regulator to recommend expanded reimbursement for Aricept, Exelon and Reminyl among patients with mild Alzheimer's disease, and for Exiba in moderate disease.